▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #1819 by analyst upside · 2026-06-27
DNTH
Dianthus Therapeutics, Inc.
Healthcare · Market Cap $5B · P/E 0x
ANALYST PRICE TARGET
+33.9%
implied upside to consensus target
Current Price $95.35
Consensus Target $127.67
Bull Target $200.0
Bear Target $98.0
Analysts Covering 12
ANALYST CONSENSUS — BUY
Strong Buy
0
Buy
12
Hold
0
Sell
0
52-Week Low $17.27
52-Week High $96.78
YTD Return +140.3%
FUNDAMENTALS
Market Cap $5B
P/E Ratio (TTM) N/A
Forward P/E -20.5x
EPS (TTM) $-4.23
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) $1M
Profit Margin N/A
52-WEEK RANGE
52-Week Low $17.27
52-Week High $96.78
Current Price $95.35
Bear Target $98.0
Bull Target $200.0
● Now $95.35 ● Target $127.67
TRADING DATA
Avg Volume 834K
YTD Return +140.3%
Analyst Count 12
Consensus Buy
Upside to Target +33.9%
Last Updated 2026-06-27

ANALYST SUMMARY

Dianthus Therapeutics, Inc. (DNTH) is currently trading at $95.35 with a Wall Street consensus price target of $127.67, implying potential upside of 33.9% over the next 12 months. 12 analysts currently cover DNTH, with a consensus rating of Buy — 100% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $200.0, while the most cautious has a target of $98.0.

DNTH operates in the Healthcare sector with a market capitalisation of $5B. The stock is up 140.3% year-to-date and is currently trading near the upper end of its 52-week range of $17.27 – $96.78.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

GRFS +47.0%
Grifols, S.A.
$5B · P/E 10.6x · Buy
INDV +21.2%
Indivior Pharmaceuticals, Inc.
$5B · P/E 21.2x · Buy
ACAD +25.0%
ACADIA Pharmaceuticals Inc.
$4B · P/E 11.5x · Buy
STVN +37.1%
Stevanato Group S.p.A.
$5B · P/E 30.8x · Buy
MMSI +24.8%
Merit Medical Systems, Inc.
$4B · P/E 30.9x · Buy

RECENT ANALYST CALLS

Upgrade/downgrade history for DNTH, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Wedbush — Reiterated
Outperform → Outperform 2026-05-06 Building track record
Wolfe Research ● Initiated
Outperform 2026-04-09 Building track record
Wells Fargo ● Initiated
Overweight 2026-03-19 Building track record
Wedbush — Reiterated
Outperform → Outperform 2026-03-12 Building track record
Wedbush — Reiterated
Outperform → Outperform 2026-03-10 Building track record
Raymond James ↑ Upgrade
Outperform → Strong Buy 2026-03-10 Building track record
Baird — Reiterated
Outperform → Outperform 2026-03-10 Building track record
Clear Street — Reiterated
Buy → Buy 2026-03-10 Building track record
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
—
out of 100
Coverage depth
0/30
Consensus clarity
0/30
Vote unanimity
0/25
Rating stability
0/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call — not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →